SHIM
PHAT icon

Stone House Investment Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Stone House Investment Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87 Hold
8
– – ﹤0.01% 1298
2026
Q1 		$89 Buy
+8
New +$101 ﹤0.01% 1016

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Stone House Investment Management's PHAT Position: Q2 2026 in Review

Stone House Investment Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 8 shares worth $87. The position accounts for ﹤0.01% of the portfolio, ranked #1298.

Stone House Investment Management first reported a position in PHAT in Q1 2026 and has held it in 2 quarters since. The position peaked at $89 in Q1 2026. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Stone House Investment Management held 8 shares of Phathom Pharmaceuticals worth $87 as of Q2 2026.
  • Stone House Investment Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
  • Phathom Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1298 holding.
  • Stone House Investment Management first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Stone House Investment Management's Phathom Pharmaceuticals position peaked at $89 in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.